Chronic kidney disease(CKD)
Conditions
Interventions
additional medication of losartan (50mg/d) for 2 months to the preceding 2 month-treatment with HCTZ (12.5mg/d)
additional medication of HCTZ (12.5mg/d) for 2 months to the preceding 2 month-treatmen
Sponsors
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. age 20y or more 2. CKD based on K/DOQI criteria 3. Office BP >130/80 on at least one occasion before enrollment 4. documented informed consent
Exclusion criteria
Exclusion criteria: 1. previous treatment with ARB or diuretics 2 months before enrollment 2. contraindication to losartan or HCTZ (history of the allergic reaction, bilateral renal artery stenosis) 3. presence or possibility of pregnancy 4. HbA1c >9.0 % 5. GOT >100, or GPT >85 6. endocrine hypertension 7. accelerated or malignant hypertension 8. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 9. nephrotic syndrome (serum albumin <2.5 g/dl) 10. patients under hemodialysis therapy 11. any reason for ineligibility suggested by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the tubular sodium load (PNa x GFR), tubular sodium reabsorption, and urinary sodium excretion, circadian rhythms of blood pressure and natriuresis | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary angiotensinogen excretion (intrarenal RAS activity), ultrasonic examination of the kidney (RI), heart rate variability obtained by holter ECG (sympathetic activity) | — |
Countries
Japan
Contacts
Public ContactToshiyuki Miura
Nagoya City University Graduate School of Medical Sciences Cardio-Renal Medicine and Hypertension
Outcome results
None listed